Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL

Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. SARS-CoV-2 vaccines created an opportunity for new insights in vaccine timing because patients were challenge...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases
Main Authors Chong, Elise A, Kumashie, Kingsley Gideon, Chong, Emeline R, Fabrizio, Joseph, Gupta, Aditi, Svoboda, Jakub, Barta, Stefan K, Walsh, Kristy M, Napier, Ellen B, Lundberg, Rachel K, Nasta, Sunita D, Gerson, James N, Landsburg, Daniel J, Gonzalez, Joyce, Gaano, Andrew, Weirick, Madison E, McAllister, Christopher M, Awofolaju, Moses, John, Gavin N, Kammerman, Shane C, Novaceck, Josef, Pajarillo, Raymone, Lundgreen, Kendall A, Tanenbaum, Nicole, Gouma, Sigrid, Drapeau, Elizabeth M, Adamski, Sharon, D'Andrea, Kurt, Pattekar, Ajinkya, Hicks, Amanda, Korte, Scott, Sharma, Harsh, Herring, Sarah, Williams, Justine C, Hamilton, Jacob T, Bates, Paul, Hensley, Scott E, Prak, Eline T Luning, Greenplate, Allison R, Wherry, E John, Schuster, Stephen J, Ruella, Marco, Vella, Laura A
Format Journal Article
LanguageEnglish
Published United States 04.03.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. SARS-CoV-2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic mRNA vaccine response in retrospective and prospective cohorts with lymphoma and CLL, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active therapies, but non-response was also common within observation and post-treatment groups. Total IgA and IgM correlated with successful vaccine response. In individuals treated with CART-19, non-response was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to allow individualized vaccine timing.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1537-6613
1537-6613
DOI:10.1093/infdis/jiae106